Cauda	cauda	O	O	OTHERS	I
equina	equina	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
after	after	O	O	O	O
spinal	spinal	O	O	O	O
anaesthesia	anaesthesia	O	O	O	O
with	with	O	O	O	O
hyperbaric	hyperbaric	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
lignocaine	lignocaine	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
six	six	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
cauda	cauda	O	O	OTHERS	I
equina	equina	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
reported	reported	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
Swedish	swedish	O	O	O	O
Pharmaceutical	pharmaceutical	O	O	O	O
Insurance	insurance	O	O	O	O
1993	1993	O	O	O	O
-	-	O	O	O	O
1997.Six	1997.six	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
cauda	cauda	O	O	OTHERS	I
equina	equina	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
with	with	O	O	O	O
varying	varying	O	O	O	O
severity	severity	O	O	O	O
were	were	O	O	O	O
reported	reported	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
Swedish	swedish	O	O	O	O
Pharmaceutical	pharmaceutical	O	O	O	O
Insurance	insurance	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
period	period	O	O	O	O
1993	1993	O	O	O	O
-	-	O	O	O	O
1997	1997	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
spinal	spinal	O	O	O	O
anaesthesia	anaesthesia	O	O	O	O
using	using	O	O	O	O
hyperbaric	hyperbaric	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
lignocaine	lignocaine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Five	five	O	O	O	O
cases	cases	O	O	O	O
had	had	O	O	O	O
single-shot	single-shot	O	O	O	O
spinal	spinal	O	O	O	O
anaesthesia	anaesthesia	O	O	O	O
and	and	O	O	O	O
one	one	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
repeat	repeat	O	O	O	O
spinal	spinal	O	O	O	O
anaesthetic	anaesthetic	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
inadequate	inadequate	O	O	O	O
block	block	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
hyperbaric	hyperbaric	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
lignocaine	lignocaine	CHEMICALS	O	OTHERS	I
administered	administered	O	O	O	O
ranged	ranged	O	O	O	O
from	from	O	O	O	O
60	60	O	O	O	O
to	to	O	O	O	O
120	120	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

Three	three	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
cases	cases	O	O	O	O
were	were	O	O	O	O
most	most	O	O	O	O
likely	likely	O	O	O	O
caused	caused	O	O	O	O
by	by	O	O	O	O
direct	direct	O	O	O	O
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
hyperbaric	hyperbaric	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
lignocaine	lignocaine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
3	3	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
direct	direct	O	O	O	O
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
probable	probable	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
unfortunately	unfortunately	O	O	O	O
radiological	radiological	O	O	O	O
investigations	investigations	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
done	done	O	O	O	O
to	to	O	O	O	O
definitely	definitely	O	O	O	O
exclude	exclude	O	O	O	O
a	a	O	O	O	O
compressive	compressive	O	O	O	O
aetiology	aetiology	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
cases	cases	O	O	O	O
sustained	sustained	O	O	O	O
permanent	permanent	O	O	O	O
neurological	neurological	O	O	OTHERS	I
deficits	deficits	O	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
recommend	recommend	O	O	O	O
that	that	O	O	O	O
hyperbaric	hyperbaric	O	O	O	O
lignocaine	lignocaine	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
administered	administered	O	O	O	O
in	in	O	O	O	O
concentrations	concentrations	O	O	O	O
not	not	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
2	2	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
total	total	O	O	O	O
dose	dose	O	O	O	O
preferably	preferably	O	O	O	O
not	not	O	O	O	O
exceeding	exceeding	O	O	O	O
60	60	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

